RespireRx Pharmaceuticals Inc.
DelistedCIK 849636fmd_1MSBRNFS0Y58GJEX8H65NA36BTManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2023, 54 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 0 | – | – | – | – | – | – | – |
| Net interest income | – | – | 0 | – | – | – | – | – | – | – |
| Research and development | 0 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 0 |
| Total operating expenses | 1 | 4 | 5 | 8 | 4 | 2 | 2 | 3 | 3 | 2 |
| Operating income | (1) | (4) | (5) | (8) | (4) | (2) | (2) | (3) | (3) | (2) |
| Interest expense | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Net income | (1) | (3) | (6) | (9) | (4) | (3) | (2) | (4) | (3) | (2) |
| Net income to common shareholders | (1) | (13) | (6) | (9) | (4) | – | (2) | (6) | (4) | (4) |